Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive <i>EGFR</i> mutations: NEJ005/TCOG0902.
Satoshi Oizumi(Hokkaido University), Koichi Hagiwara(Jichi Medical University), Akihiko Gemma(Nippon Medical School), Hiroshi Isobe, Kunihiko Kobayashi(Saitama International Medical Center), Koichi Minato, Ichiro Kinoshita(Hokkaido University), Akira Inoue(Tohoku University Hospital), Toshiyuki Harada(Hokkaido hospital), Shunichi Sugawara(Sendai Kousei Hospital), Masaru Nishitsuji(Ishikawa Prefectural Central Hospital), Satoshi Morita(Kyoto University), Yuka Fujita, Minoru Kurihara(Japan Clinical Cancer Research Organization), Hirohisa Yoshizawa(Niigata University Medical and Dental Hospital), Kazuhiko Ito(Niigata City General Hospital), Toshihiro Nukiwa(Tohoku University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Masao Harada(Shikoku Cancer Center)
Cited by 6
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953